The legal battle over access to the abortion drug mifepristone intensified earlier this month when a conservative-majority panel of the U.S. 5th Circuit Court of Appeals temporarily blocked mail-order distribution of the medication. The decision came in response to a lawsuit filed by Louisiana, which challenged the Biden administration’s 2021 FDA regulations permitting the drug to be prescribed via telemedicine. Louisiana argued that this federal policy infringed on its sovereignty by allowing residents to receive mifepristone despite the state's abortion restrictions.

The 5th Circuit’s nationwide injunction, issued in late May, effectively barred women in all states from obtaining mifepristone through the mail, rather than limiting the prohibition to states with abortion bans. Mifepristone is a critical component of a two-pill regimen used in approximately 60 percent of medication abortions in the United States.

Pharmaceutical manufacturers quickly appealed to the Supreme Court, which intervened within days to maintain the FDA’s existing rules while the underlying legal dispute proceeds in lower courts. The Supreme Court’s 7-2 ruling allowed continued mail access to mifepristone, providing temporary relief to patients nationwide amid ongoing uncertainty. The close timing and sudden nature of the lower court’s injunction underscored the precariousness of abortion care access following the Supreme Court’s 2022 Dobbs decision that overturned Roe v. Wade and returned abortion regulation to the states.

The case has drawn starkly divided reactions. Supporters of abortion rights hailed the Supreme Court’s intervention as critical to maintaining access and safeguarding what they see as essential health care. They also warned that the underlying legal fight, especially given the dissenting opinions, signals persistent threats to abortion access remain imminent.

In dissent, Justices Samuel Alito and Clarence Thomas criticized the majority for upholding FDA rules they viewed as illegally facilitating abortion distribution. Thomas referenced the Comstock Act of 1873—a law prohibiting the use of postal services to send abortion-inducing drugs—and suggested the government’s enforcement undermines existing statutory bans. Alito accused federal authorities, certain states, and the pharmaceutical industry of conspiring to circumvent the Dobbs ruling by expanding telehealth access to mifepristone, pointing out that abortion rates in Louisiana have increased since 2022 despite restrictions.

Some conservative advocates argue that future enforcement could be bolstered by revising FDA protocols or leveraging criminal statutes, including the revival of the Comstock Act, which has long been considered obsolete. Observers caution that such strategies may lead to prosecutions targeting not only patients but also health care providers and drug manufacturers.

Meanwhile, former President Donald Trump has faced criticism from some pro-life activists for not taking more decisive action to challenge FDA policies or assist states in enforcing abortion bans. Whether the legal battles will result in permanent restrictions on mifepristone distribution remains uncertain, but ongoing court decisions will likely continue to shape the landscape of medication abortion access in the United States.